- About ELS
- Therapeutic Areas
- Operational Metrics
- Contact Us
The most common disease forms seen under gastroenterology are hepatitis and cirrhosis of the liver. The most common cause of acute viral hepatitis in India is hepatitis E virus (HEV). Hepatitis B virus (HBV) is the second most common, affecting over 50 million people. India falls in the intermediate endemicity zone (prevalence of 2–7%, with an average of 4%), with a disease burden of about 50 million. Inflammatory bowel disease (IBD) is now being increasingly diagnosed in clinical practice. Over 12,00,000 people in India are affected by IBD annually.
The incidence of UC in Asian countries ranges from 0.5–31.5 per 1,00,000 population, which is lower than the incidence rate of 6 per 1,00,000 recorded in India. The prevalence of UC is significant, in the range of 42-44 per 1,00,000 person-years. In India, the males are about eighteen times more susceptible to peptic ulcer related mortality than females. Per the latest statistics available, nearly 2,00,000 people in India die of terminal liver disease.
Other diseases of the digestive system affecting the esophagus, stomach, intestines, liver and pancreas constitute a major public health issue in India. Of the variedly other diseases seen under gastroenterology cirrhosis of the liver, chronic cholecystitis, and cholelithiasis are mention-worthy. Our institute has conducted a whole number of studies in the area of gastroenterology and we are confident that we can assist you with your next study.
Excel Life Sciences (ELS) has successfully developed one among the few most experienced and sophisticated networks of gastroenterology investigators and investigative sites in India. Each site has absolute access to a large and diverse patient pool. Using our databases of detailed site information, demographics and epidemiology data we can quickly determine if India is the right fit for your study. In addition, ELS can quickly mobilize a team of experienced project managers to conduct a study feasibility analysis and determine the appropriate sites and availability of patients.
We ensure that gastroenterology clinical trials are conducted according to ICH – GCP guidelines and meet the highest standards of ethics and integrity.